Lifevantage Corporation Announces Appointment of James J. Krejci as CEO

DENVER, Dec 27, 2006 (BUSINESS WIRE) -- Lifevantage Corporation (OTCBB: LFLT), maker of Protandim(R), today announced that Mr. James J. Krejci has been appointed Chief Executive Officer by the Board of Directors. Mr. Krejci has been a member of the Company's Board of Directors since April 2005 and the Vice Chairman of the Board since October 2006. Mr. Krejci is a seasoned top executive with extensive national and international experience in consumer, medical, and high-tech products and services. He has significant operating experience and has been employed at the 3M company, GE, Becton Dickinson, and IGT.

In addition, on December 20, 2006, Dr. Larry Gold resigned as a member of the Board of Directors and as a member of the Science Committee and Scientific Advisory Board of the Board. On December 22, 2006, Mr. William L. Lister resigned as a member of the Board of Directors and as a member of the Compensation, Marketing, and Science Committees of the Board.

"I am pleased to serve as Chief Executive Officer of Lifevantage, and look forward to building our organization and our product, Protandim(R)," said Mr. Krejci. "My service on the Board of Directors gives me immediate familiarity with the organization."

"Mr. Krejci is a dedicated member of Lifevantage's Board and we look forward to his helping us in fulfilling the potential of Lifevantage," said John Van Heuvelen, Chairman of the Board of Directors.

About Protandim(R)

Protandim(R) is a patent-pending dietary supplement that increases the body's natural antioxidant protection by inducing two protective enzymes, superoxide dismutase (SOD) and catalase (CAT). These naturally occurring enzymes become overwhelmed by free radicals as we get older. Oxidative stress (cell damage caused by free radicals) occurs as a person ages, when subjected to environmental stresses or as an associated factor in certain illnesses. TBARS are laboratory markers for oxidative stress in the body. Data from a peer-reviewed, published scientific study in men and women, sponsored by Lifevantage, show that after 30 days of taking Protandim(R), the level of circulating TBARS decreased an average of 40 percent, with this decrease shown to be maintained at 120 days. Protandim(R) strengthens a person's defenses against oxidative stress by increasing the body's natural antioxidant enzymes. For more information, please visit the Protandim(R) product web site at

About Lifevantage Corporation

Lifevantage Corporation markets Protandim(R). Lifevantage is committed to helping people achieve health and wellness for life. For more information, please visit the Company's web site at

Except for historical information contained herein, this document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, applicable common law and Securities and Exchange Commission rules. The Company uses the words "anticipate," "believe," "could," "should," "estimate," "expect," "intend," "may," "predict," "project," "plan," "target" and similar terms and phrases, including references to assumptions, to identify forward-looking statements. These forward-looking statements are based on the Company's current expectations and beliefs concerning future events affecting the Company and involve known and unknown risks and uncertainties that may cause the Company's actual results or outcomes to be materially different from those anticipated and discussed herein. These risks and uncertainties are difficult to predict accurately and may be beyond the control of the Company. The following factors are among those that may cause actual results to differ materially from our forward-looking statements: government regulators and regulations could adversely affect our business; future laws or regulations may hinder or prohibit the production or sale of our existing product and any future products; unfavorable publicity could materially hurt our business and the value of your investment; and the Company's ability to protect our intellectual property rights and the value of our product. These and other additional risk factors and uncertainties are discussed in greater detail in the Company's Annual Report on Form 10-KSB under the caption "Risk Factors", and in other documents filed the Company from time to time with the Securities and Exchange Commission. Forward-looking statements made by the Company in this news release or elsewhere speak only as of the date made. New uncertainties and risks come up from time to time, and it is impossible for the Company to predict these events or how they may affect the Company. The Company has no duty to, and does not intend to, update or revise the forward-looking statements in this news release after the date it is issued. In light of these risks and uncertainties, investors should keep in mind that the results, events or developments disclosed in any forward-looking statement made in this news release may not occur.

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.